North America Circulating Tumor Cell (CTC) Diagnostics Market

The North America circulating tumor cell (CTC) diagnostics market is expected to reach US$ 1,664.0 million by 2028 from US$ 861.6 million in 2021. The market is estimated to grow at a CAGR of 9.9% from 2021 to 2028.

Health systems in this region are witnessing a substantial increase in the prevalence of cancer. According to the International Agency for Research on Cancer (IARC), cancer burden in North America has increased to 19.3 million cases and 9.96 million cancer deaths as of 2020. A study published by the National Cancer Institute estimated the cancer incidence in the US at 1.9 million in 2021. ~0.6 million people were anticipated to die in 2021 in the US due to cancer. Thus, the increased prevalence of cancer across North America is propelling the demand for circulating tumor cell (CTC) diagnostics. The analysis and detection of circulating tumor cells assist in early patient diagnosis, and prognosis helps determine accurate treatment for the patient. The CTC diagnostics can be used to detect various types of cancers, including prostate cancer, breast cancer, colorectal cancer, kidney cancer, lymphomas, lung cancer, and melanoma. There has been a high demand for CTC diagnostics in recent years due to its reliability and accuracy in identifying the risk of the disease and monitoring its treatments.

The impact of the COVID-19 pandemic on cancer patients, cancer surveillance capacities, and the whole American health system has been notable. Reduced resources and limited healthcare capacity made cancer detection and treatment more difficult, resulting in lower incidence, higher mortality, and lower survival in the future. Because of a compromised immune system caused by cancer and/or its treatment (e.g., surgery and chemotherapy), people with active cancer are more susceptible to infectious pathogens. Thus, the risk of COVID-19 severity and mortality may be more common in cancer patients. Males; people of age 60 and above; people with a history of smoking; populations suffering from obesity, hypertension, cardiovascular disease, and diabetes have all been consistently related to an elevated risk of severe disease and/or death. Findings relating to prognosis for cancer-associated variables have proven conflicting.

With new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the circulating tumor cell (CTC) diagnostics market in North America at a good CAGR during the forecast period.

North America Circulating Tumor Cell (CTC) Diagnostics Market Revenue and Forecast to 2028 (US$ Million)

North America Circulating Tumor Cell (CTC) Diagnostics Market Segmentation       

 

By Technology

• CTC detection and Enrichment Method
• CTC Direct Detection Methods
• CTC Analysis

By Application

• Clinical/Liquid Biopsy
  • Risk Assessment
  • Screening and Monitoring
• Research
  • Cancer Stem Cell and Tumorigenesis Research
  • Drug/Therapy Development

By End-User

• Hospitals and Clinics
• Research and Academic Institutes
• Diagnostic Centers

By Country

• US
• Canada
• Mexico

Companies Mentioned

• Thermo Fisher Scientific Inc.
• Stemcell Technologies Inc.
• Qiagen
• Precision Medicine Group, Llc
• Advanced Cell Diagnostics, Inc. (Bio-Techne Corporation)
• Epic Lifesciences
• Screencell
• Ikonisys, Inc
• IVdiagnostics
• Fluxion Bioscience

North America Circulating Tumor Cell (CTC) Diagnostics Strategic Insights

Strategic insights for the North America Circulating Tumor Cell (CTC) Diagnostics provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

North America Circulating Tumor Cell (CTC) Diagnostics Report Scope

North America Circulating Tumor Cell (CTC) Diagnostics Regional Insights

The geographic scope of the North America Circulating Tumor Cell (CTC) Diagnostics refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.